Starting TRT? Monitoring, Fertility, and Prostate Questions to Discuss First

September 1, 2026Atlanta Medical Institute

Thinking about TRT in Atlanta? Discuss fertility timing, blood pressure, hematocrit, prostate monitoring, symptom goals, and adverse effects with your clinician first.

Published 2026-09-01. Many Atlanta men are curious about whether testosterone replacement therapy could help address bothersome symptoms, and just as many want a clear plan for safety and follow-up. This guide highlights the baseline and monitoring topics that typically belong in a clinician-led discussion before any testosterone therapy decision, including fertility plans, blood pressure, hematocrit, prostate considerations, symptom tracking, and potential adverse effects [7, 4, 1].

First, confirm why testosterone therapy is being considered

Testosterone products are approved for men with certain medical conditions that cause low testosterone; they are not approved to address age-related testosterone decline alone. Evaluation typically includes compatible symptoms plus low early-morning total testosterone confirmed on two separate days before therapy is considered [3, 7].

What belongs in a pre-TRT conversation?

Before deciding about therapy, a thorough conversation helps align expectations and plan monitoring. Key topics include fertility timing, blood pressure and cardiovascular history, hematocrit, prostate health, sleep and urinary symptoms, medication form, and how symptom response will be assessed over time [7, 4, 1].

Fertility plans in the next few years, because exogenous testosterone suppresses gonadotropins and sperm production and can impair fertility during treatment [7].
Blood pressure history and a plan for monitoring, given class-wide labeling that testosterone products can increase blood pressure [4].
Baseline hematocrit and a monitoring plan because therapy can raise hematocrit (erythrocytosis) [7, 1].
Prostate risk assessment appropriate to age and risk factors, including whether baseline prostate-specific antigen (PSA) testing and digital rectal examination (DRE) are indicated and how they will be reassessed early in treatment [7, 1].
Cardiovascular history and risk factors, with discussion of the evidence on major adverse cardiovascular events and other observed events in trials [2].
Sleep, snoring, or diagnosed obstructive sleep apnea, because untreated severe obstructive sleep apnea is a concern in guideline discussions [7].
Lower urinary tract symptoms or known benign prostatic hyperplasia, since bothersome urinary symptoms can worsen on therapy and warrant discussion [1, 7].
Formulation-specific safety and use topics (for example, skin-to-skin transfer precautions if a topical gel is chosen) [1].
What symptom changes would be considered meaningful, how serum testosterone targets will be individualized, and when reassessment will occur, using a clinician-led plan rather than self-adjustment [7].

Fertility planning belongs up front

Exogenous testosterone suppresses luteinizing hormone and follicle-stimulating hormone, which in turn affects intratesticular testosterone and spermatogenesis during treatment. If building a family is a near-term goal, guideline groups recommend discussing this fertility risk and potential alternatives before any therapy decision [7].

Some clinicians consider other approaches in certain settings when fertility is a near-term priority, aiming to support endogenous gonadotropin production rather than suppress it; these options, risks, and uncertainties are appropriate to review together. Do not start, stop, or change any medication without the prescribing clinician [7].

Blood pressure and cardiovascular discussion points

The FDA requires class-wide labeling changes noting that testosterone therapy can increase blood pressure; a plan for baseline blood pressure assessment and monitoring during treatment is an important part of risk discussions [4].

Large randomized data in men with confirmed hypogonadism and cardiovascular risk (TRAVERSE) found testosterone was noninferior to placebo for major adverse cardiovascular events over the study period, but higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism occurred in the testosterone group. These findings support individualized cardiovascular discussions rather than assumptions of uniform risk or benefit [2].

Regulators also emphasize that testosterone should be reserved for men with conditions that truly cause low testosterone, not for age-related decline alone—a distinction that is part of weighing risks and benefits [3].

Hematocrit and erythrocytosis: why it is checked early and often

Testosterone therapy can raise hematocrit. Guidelines advise checking hematocrit at baseline, again at approximately 3–6 months after starting therapy, and then periodically (often annually) to watch for erythrocytosis, which can prompt clinician-led adjustments if thresholds are exceeded. Many guidelines use a hematocrit threshold of about 54 percent to trigger reassessment under clinician supervision; do not make changes without the prescribing clinician [7].

Prostate considerations: baseline and early follow-up

For men in age groups where prostate cancer screening is considered, guidelines recommend baseline PSA and, when indicated, DRE before therapy. Reassessment of PSA and prostate symptoms at 3–12 months after starting therapy is advised, followed by age-appropriate shared decision-making thereafter. Urology consultation is suggested if any of the following occur: a PSA increase greater than 1.4 ng/mL within the first 12 months, a confirmed PSA above 4.0 ng/mL at any time, a prostatic abnormality on DRE, or significant worsening of lower urinary tract symptoms [7].

Product labeling also notes potential for worsening urinary symptoms in men with benign prostatic hyperplasia and highlights prostate monitoring as part of responsible use discussions [1].

Symptom goals, lab targets, and adverse effects to discuss

A shared plan outlines which symptoms will be tracked (for example, sexual function or energy) alongside serum testosterone measurements timed to the chosen formulation. Guidelines emphasize individualized targets and periodic reassessment of both symptoms and labs, rather than self-directed adjustments [7].

Potential adverse effects to review include acne or oily skin, gynecomastia, edema, elevated hematocrit, increases in PSA, and possible worsening of sleep apnea or lower urinary tract symptoms. Topical preparations can cause application-site reactions and carry a risk of testosterone transfer to others with direct skin contact; safe-use instructions are part of counseling. Any new or worsening symptoms are typically reviewed with the prescribing clinician; do not make medication changes without the prescribing clinician [1, 7].

Formulation matters for counseling and monitoring

Different formulations have different application, absorption, and monitoring considerations. For example, transdermal gels require attention to application technique and precautions to prevent transfer to others; injectables, transdermal systems, and other forms have their own timing and dose-adjustment discussions. Review formulation-specific counseling and follow-up with your clinician [1, 7].

A practical pre-TRT and follow-up checklist to review with your clinician

Confirm indication: discuss compatible symptoms plus low morning total testosterone on two separate days, and how other contributing conditions will be evaluated first [7, 3].
Fertility: discuss near-term family plans and how therapy may affect spermatogenesis; consider alternatives when fertility is a near-term goal [7].
Blood pressure: discuss baseline readings and agree on a monitoring plan during therapy in light of class labeling about blood pressure increases [4].
Hematocrit: discuss baseline testing, rechecking around 3–6 months, then periodic monitoring to assess for erythrocytosis; thresholds for reassessment are clinician-guided [7].
Prostate: for men in screening age ranges or with risk factors, discuss baseline PSA and DRE and plan for reassessment at 3–12 months; know the typical triggers for urology referral [7].
Sleep and urinary symptoms: review obstructive sleep apnea symptoms and lower urinary tract symptoms or benign prostatic hyperplasia history [7, 1].
Symptom goals and labs: agree on which symptoms and lab values will be used to gauge response, and when these will be checked based on your formulation; avoid self-adjustment [7].
Formulation-specific education: review administration technique and precautions (for example, gel transfer avoidance) [1].
Adverse effects: review common reactions to watch for, and how to contact your clinician if they occur; do not make medication changes without the prescribing clinician [1, 7].

Considering care in Atlanta

If you are comparing testosterone clinics in Atlanta, look for physician-led programs that emphasize appropriate diagnosis, counseling about fertility, structured blood pressure and hematologic monitoring, and age- and risk-appropriate prostate discussions [7]. Atlanta Medical Institute offers physician-supervised hormone replacement therapy services and can discuss whether monitoring elements like those described here fit your situation [5, 6].

Limitations, uncertainties, and why plans differ

Not all questions are settled. Large cardiovascular safety data in confirmed hypogonadism are reassuring for major adverse cardiovascular events over the studied period but also identified higher rates of selected events, underscoring the need for individualized risk discussions. Different populations and longer-term outcomes may not mirror trial conditions [2].

The FDA continues to emphasize appropriate indications and has added class-wide labeling about blood pressure increases, reflecting evolving safety information. Monitoring plans should account for these considerations rather than assuming uniform safety [3, 4].

Guidelines note that testosterone therapy during treatment can impair spermatogenesis and advise discussing alternatives when near-term fertility is a priority; follow-up is individualized based on goals and comorbidities [7].

Can testosterone therapy be used if I want to conceive in the near future?

Exogenous testosterone suppresses gonadotropins and can affect spermatogenesis during treatment. When near-term conception is a goal, clinicians typically discuss timing and possible alternatives before any therapy decision. Medication changes should only be made with the prescribing clinician [7].

How often are blood tests and blood pressure checks done on TRT?

Guidelines describe monitoring approaches that often include baseline hematocrit with reassessment around the first few months and then periodically; for men in prostate-screening age ranges, PSA is commonly reassessed within the first year. Product labeling emphasizes blood pressure monitoring. The exact schedule is individualized by the clinician and formulation [7, 4].

Does TRT raise my heart or stroke risk?

In a large randomized trial of men with confirmed hypogonadism and cardiovascular risk, major adverse cardiovascular events were similar between testosterone and placebo, while some events—such as atrial fibrillation, acute kidney injury, and pulmonary embolism—were more frequent with testosterone. FDA class labeling also notes blood pressure increases with testosterone products. These findings support individualized cardiovascular discussions [2, 4].

What prostate changes should be watched once therapy starts?

Guidelines outline situations that may prompt discussion with a urologist, including notable PSA rises within the first year, PSA levels above commonly used thresholds, abnormal DRE findings, or significant changes in urinary symptoms [7].

Which side effects should I talk about with my clinician right away?

Labeling and guidelines discuss reactions such as acne or oily skin, application-site reactions with gels, edema, breast tenderness or gynecomastia, elevated hematocrit, increases in PSA, and potential worsening of obstructive sleep apnea or lower urinary tract symptoms. Any new or worsening symptoms are typically reviewed with the prescribing clinician; do not make medication changes without the prescribing clinician [1, 7].

Questions you can bring to your clinician

Based on my symptoms and two separate early-morning tests, do I meet criteria for hypogonadism that would justify considering testosterone therapy? How will other causes be evaluated first [7, 3]?
How will therapy affect my short- and long-term family-building plans, and what alternatives might we consider if fertility is a near-term goal [7]?
What is our plan for checking blood pressure, hematocrit, and, if indicated, PSA in the first year and beyond [4, 7]?
Which formulation fits my goals and routine, and what specific administration and safety steps do I need to follow (for example, preventing gel transfer) [1]?
What symptoms and lab values will we use to judge benefit versus risk, and at what intervals will we reassess before making any clinician-led changes [7]?
Given my cardiovascular history, how do the TRAVERSE findings and FDA labeling inform our shared decision-making [2, 4]]?
What signs or symptoms should prompt me to contact the clinic between scheduled visits, and how should I do that [1, 7]?

Sources

When to Talk With a Clinician

Contact Atlanta Medical Institute to discuss your goals, health history, and appropriate options with a qualified clinician.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Medication and hormone-treatment eligibility, risks, monitoring, and results vary; consult a qualified healthcare professional.